Spero Therapeutics (2HA) Financial Statements
Spero Therapeutics Financial Overview
Spero Therapeutics's market cap is currently $55.09M. The company's EPS TTM is $0.14; its P/E ratio is 7.57; Spero Therapeutics is estimated to report earnings on November 16, 2026, and the estimated EPS forecast is $-0.42. See an overview of income statement, balance sheet, and cash flow financials.
| Dec 25 | Dec 24 | Dec 23 | Dec 22 | Mar 22 | |
|---|---|---|---|---|---|
| Income Statement | |||||
| Total Revenue | $ 59.62M | $ 47.98M | $ 103.78M | $ 48.58M | $ 3.07M |
| Gross Profit | $ 59.62M | $ -48.78M | $ 52.34M | $ 48.58M | $ 3.07M |
| Operating Income | $ -24.00K | $ -73.36M | $ 21.48M | $ -42.20M | $ -87.97M |
| EBITDA | $ 8.83M | $ -72.48M | $ 27.15M | $ -42.94M | $ -87.17M |
| Net Income | $ 8.57M | $ -68.57M | $ 22.81M | $ -46.41M | $ -89.76M |
| Balance Sheet | |||||
| Cash & Short-Term Investments | $ 40.27M | $ 52.89M | $ 76.33M | $ 109.11M | $ 146.40M |
| Total Assets | $ 68.92M | $ 110.54M | $ 182.39M | $ 124.80M | $ 171.07M |
| Total Debt | $ 2.90M | $ 4.30M | $ 5.54M | $ 6.65M | $ 7.33M |
| Net Debt | $ -37.37M | $ -48.59M | $ -70.79M | $ -102.46M | $ -105.25M |
| Total Liabilities | $ 9.90M | $ 64.42M | $ 75.50M | $ 48.87M | $ 82.78M |
| Stockholders' Equity | $ 59.02M | $ 46.12M | $ 106.89M | $ 75.93M | $ 88.29M |
| Cash Flow | |||||
| Free Cash Flow | $ -12.62M | $ -23.44M | $ -32.99M | $ -7.73M | $ -64.35M |
| Operating Cash Flow | $ -12.62M | $ -23.44M | $ -32.99M | $ -7.73M | $ -64.35M |
| Investing Cash Flow | $ 0.00 | $ 0.00 | $ 0.00 | $ 33.81M | $ 7.67M |
| Financing Cash Flow | $ 0.00 | $ 0.00 | $ 221.00K | $ -29.55M | $ 84.05M |
Currency in USD